<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur J Case Rep Intern Med</journal-id><journal-id journal-id-type="iso-abbrev">Eur J Case Rep Intern Med</journal-id><journal-title-group><journal-title>European Journal of Case Reports in Internal Medicine</journal-title></journal-title-group><issn pub-type="epub">2284-2594</issn><publisher><publisher-name>SMC Media Srl</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6346900</article-id><article-id pub-id-type="doi">10.12890/2016_000537</article-id><article-id pub-id-type="publisher-id">537-1-3366-1-10-20161219</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>A New Mutation Causing Progressive Familiar Intrahepatic Cholestasis Type 3 in Association with Autoimmune Hepatitis </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Oliveira</surname><given-names>Hugo M.</given-names></name><xref ref-type="aff" rid="af1-537-1-3366-1-10-20161219">1</xref></contrib><contrib contrib-type="author"><name><surname>Pereira</surname><given-names>Cláudia</given-names></name><xref ref-type="aff" rid="af1-537-1-3366-1-10-20161219">1</xref></contrib><contrib contrib-type="author"><name><surname>Santos-Silva</surname><given-names>Ermelinda</given-names></name><xref ref-type="aff" rid="af2-537-1-3366-1-10-20161219">2</xref><xref ref-type="aff" rid="af5-537-1-3366-1-10-20161219">5</xref></contrib><contrib contrib-type="author"><name><surname>Pinto-Basto</surname><given-names>Jorge</given-names></name><xref ref-type="aff" rid="af3-537-1-3366-1-10-20161219">3</xref></contrib><contrib contrib-type="author"><name><surname>Vizcaíno</surname><given-names>José R.</given-names></name><xref ref-type="aff" rid="af4-537-1-3366-1-10-20161219">4</xref></contrib><contrib contrib-type="author"><name><surname>Pessegueiro-Miranda</surname><given-names>Helena</given-names></name><xref ref-type="aff" rid="af1-537-1-3366-1-10-20161219">1</xref><xref ref-type="aff" rid="af5-537-1-3366-1-10-20161219">5</xref><xref ref-type="aff" rid="af6-537-1-3366-1-10-20161219">6</xref></contrib></contrib-group><aff id="af1-537-1-3366-1-10-20161219">
<label>1</label>Liver and Pancreatic Transplantation Unit, Centro Hospitalar do Porto – Hospital de Santo António, Porto, Portugal</aff><aff id="af2-537-1-3366-1-10-20161219">
<label>2</label>Gastroenterology Unit, Pediatrics Division, Departamento da Criança e do Adolescente, Centro Materno-Infantil do Norte, Porto, Portugal</aff><aff id="af3-537-1-3366-1-10-20161219">
<label>3</label>CGC Genetics/Centro Genética Clinica, Porto, Portugal</aff><aff id="af4-537-1-3366-1-10-20161219">
<label>4</label>Pathology Unit, Centro Hospitalar do Porto – Hospital de Santo António Porto, Portugal</aff><aff id="af5-537-1-3366-1-10-20161219">
<label>5</label>Instituto de Ciências Biomédicas Abel Salazar (ICBAS) - Universidade do Porto, Porto, Portugal</aff><aff id="af6-537-1-3366-1-10-20161219">
<label>6</label>Instituto de Saúde Publica da Universidade do Porto (ISPUP) - Universidade do Porto, Porto, Portugal</aff><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>27</day><month>3</month><year>2017</year></pub-date><volume>4</volume><issue>2</issue><elocation-id>000537</elocation-id><history><date date-type="received"><day>21</day><month>11</month><year>2016</year></date><date date-type="accepted"><day>04</day><month>12</month><year>2016</year></date></history><permissions><copyright-statement>© EFIM 2016</copyright-statement><copyright-year>2016</copyright-year><license><license-p>This article is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Commons Attribution Non-Commercial 4.0 License</ext-link></license-p></license></permissions><abstract><sec><title><text><SENT sid="1" pm="."><plain>Background </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>Some patients exhibit features of both autoimmune hepatitis (AIH) and primary sclerosing cholangitis (PSC). </plain></SENT>
<SENT sid="3" pm="."><plain>Similarly, patients with progressive familial intrahepatic cholestasis type 3 (PFIC3) may share histological features with PSC. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="4" pm="."><plain>Case report </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="5" pm="."><plain>We report the case of a 22-year-old man who, since he was 5 years of age, has presented with pruritus, an approximately ninefold elevation of aminotransferases, and γ-glutamyl transferase levels ~10 times the upper limit. </plain></SENT>
<SENT sid="6" pm="."><plain>Initially he was diagnosed with an overlap syndrome of small duct PSC plus AIH. </plain></SENT>
<SENT sid="7" pm="."><plain>However, fluctuations in liver enzymes were observed over the following years. </plain></SENT>
<SENT sid="8" pm="."><plain>Analysis of the ABCB4 gene indicated the diagnosis of PFIC3, revealing a mutation not previously reported. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="9" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="10" pm="."><plain>With this case report we aim to describe a new mutation, raise awareness of this rare pathology and highlight the importance of genetic testing of the ABCB4 gene in patients with autoimmune liver disease (mainly small duct PSC) with incomplete response to immunosuppressive treatment. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="11" pm="."><plain>LEARNING POINTS </plain></SENT>
</text></title><list list-type="bullet"><list-item><p><SecTag type="ABS"><text><SENT sid="12" pm="."><plain>Autoimmune liver diseases have a wide spectrum of manifestations. </plain></SENT>
</text></SecTag></p></list-item><list-item><p><SecTag type="ABS"><text><SENT sid="13" pm="."><plain>Cholangiopathies such as ABCB4 deficiency have histological features quite similar to those seen in small duct primary sclerosing cholangitis. </plain></SENT>
</text></SecTag></p></list-item><list-item><p><SecTag type="ABS"><text><SENT sid="14" pm="."><plain>The new mutation of the ABCB4 gene described in this article is compatible with the diagnosis of progressive familial intrahepatic cholestasis type 3, which is probably less rare than usually thought. </plain></SENT>
</text></SecTag></p></list-item></list></sec></abstract><SecTag type="KEYWORD"><kwd-group><kwd>ABCB4</kwd><kwd>autoimmune hepatitis</kwd><kwd>primary sclerosing cholangitis</kwd><kwd>progressive familial intrahepatic cholestasis</kwd></kwd-group></SecTag></article-meta></front><body><SecTag type="INTRO"><sec sec-type="intro"><title><text><SENT sid="15" pm="."><plain>INTRODUCTION </plain></SENT>
</text></title><p><text><SENT sid="16" pm="."><plain>Autoimmune liver diseases have a wide spectrum of manifestations. </plain></SENT>
<SENT sid="17" pm="."><plain>Some patients present with features of both autoimmune hepatitis (AIH) and cholestatic diseases: primary sclerosing cholangitis (PSC) or primary biliary cholangitis (PBC). </plain></SENT>
<SENT sid="18" pm="."><plain>AIH is a complex disease of the hepatic parenchyma characterized by increased activity of serum aminotransferases, hypergammaglobulinaemia, circulating autoantibodies and interface hepatitis on liver histology[1,2]. </plain></SENT>
<SENT sid="19" pm="."><plain>PSC is a cholestatic liver disease of unknown aetiology characterized by an inflammatory and fibrotic process affecting intra- and extra-hepatic bile ducts[3]. </plain></SENT>
<SENT sid="20" pm="."><plain>The diagnosis of PSC is assumed in patients with elevated serum markers of cholestasis, serum alkaline phosphatase (AP) or γ-glutamyl transferase (γ-GT), and typical bile duct changes revealed by magnetic resonance cholangiography (MRC) or endoscopic cholangiopancreatography (ERCP)[3,4]. </plain></SENT>
<SENT sid="21" pm="."><plain>Some patients have clinical, biochemical and histological features compatible with PSC, but a normal image study, and are classified as having small duct PSC[5]. </plain></SENT>
</text></p><p><text><SENT sid="22" pm="."><plain>The co-existence of features of AIH and features of PSC, commonly referred as ‘overlap syndromes’, has been described in children and adults[6,7]. </plain></SENT>
<SENT sid="23" pm="."><plain>Around 10% of patients with typical AIH have histological features of bile duct injury, thus making the diagnosis of small duct PSC unclear[8]. </plain></SENT>
<SENT sid="24" pm="."><plain>Likewise, patients with other cholangiopathies such as ABCB4 deficiency have histological features quite similar to those seen with small duct PSC[9]. </plain></SENT>
<SENT sid="25" pm="."><plain>Progressive familial intrahepatic cholestasis type 3 (PFIC3), caused by a genetic defect on the ABCB4 gene, belongs to a heterogeneous group of autosomal recessive liver disorders, with childhood predominance, which causes cholestasis of hepatocellular origin[10]. </plain></SENT>
</text></p></sec></SecTag><SecTag type="CASE"><sec><title><text><SENT sid="26" pm="."><plain>CASE REPORT </plain></SENT>
</text></title><p><text><SENT sid="27" pm="."><plain>We describe the case of a 22-year-old man admitted to our outpatient clinic when he was 11 years old. </plain></SENT>
<SENT sid="28" pm="."><plain>He had presented with pruritus without jaundice since he was 5 years of age and his past medical records revealed elevation of alanine (ALT) and aspartate (AST) aminotransferase up to nine times the upper limit (UL) and of γ-GT up to ten times the UL. </plain></SENT>
<SENT sid="29" pm="."><plain>His family history was unremarkable except for the presence of PBC in his paternal grandmother (Fig. 1). </plain></SENT>
</text></p><p><text><SENT sid="30" pm="."><plain>On admission, blood tests revealed: total bilirubin 0.84 mg/dl, AST 96 IU/l, ALT 165 IU/l, γ-GT 219 IU/l and AP 577 IU/l. </plain></SENT>
<SENT sid="31" pm="."><plain>Ultrasound and MRC showed a normal sized and shaped liver, with normal intra- and extra-hepatic bile ducts. </plain></SENT>
<SENT sid="32" pm="."><plain>Immunological tests revealed: IgG 1440 mg/dl, antinuclear antibody 1/1280 with a nucleolar pattern and an anti-smooth-muscle antibody 1/160. </plain></SENT>
<SENT sid="33" pm="."><plain>Liver histology revealed preserved lobular architecture, portal space expansion due to polymorphic inflammatory infiltrate, a ductal lesion with lymphocytic invasion and occasional periductal fibrosis and ductular proliferation but no interface hepatitis. </plain></SENT>
<SENT sid="34" pm="."><plain>Nevertheless, a trial of immunosuppression was started with prednisolone and azathioprine without improvement of aminotransferase levels and persisting high levels of γ-GT and AP. </plain></SENT>
<SENT sid="35" pm="."><plain>The diagnosis of small duct PSC was proposed, azathioprine and prednisolone were withdrawn and the patient was treated with ursodeoxycholic acid, exhibiting fluctuating levels of cholestasis (Fig. 2). </plain></SENT>
</text></p><p><text><SENT sid="36" pm="."><plain>Four years later he presented with an increase in AST and ALT levels and a similar immunological study. </plain></SENT>
<SENT sid="37" pm="."><plain>A second liver biopsy (Fig. 3) showed portal expansion with polymorphic inflammatory infiltrate with lymphocytic predominance and interface and intra-lobular necro-inflammatory activity. </plain></SENT>
<SENT sid="38" pm="."><plain>The diagnosis of an overlap syndrome (small duct PSC+AIH type 1) was made and prednisolone plus azathioprine were started with normalization of AST and ALT. </plain></SENT>
<SENT sid="39" pm="."><plain>Over the following years, we observed fluctuations in liver enzyme levels (Fig. 2), unrelated to the levels or type of immunosuppression. </plain></SENT>
</text></p><p><text><SENT sid="40" pm="."><plain>We searched for mutations on the ABCB4 gene. </plain></SENT>
<SENT sid="41" pm="."><plain>Complete sequencing of the ABCB4 gene was performed using the sequence NM_000443.3. </plain></SENT>
<SENT sid="42" pm="."><plain>The patient had two mutated alleles in heterozygosity: c.874A&gt;T and c.3680T&gt;C. </plain></SENT>
<SENT sid="43" pm="."><plain>The genetic study of his parents showed the presence of heterozygous mutations in the ABCB4 gene: c.874A&gt;T (p.Lys292*) in his father and c.3680T&gt;C (p.Ile1227Thr) in his mother. </plain></SENT>
<SENT sid="44" pm="."><plain>The global analysis revealed that the biallelic distribution of the ABCB4 mutants in our patient is compatible with the diagnosis of PFIC3, which due to a variant not previously described. </plain></SENT>
</text></p></sec></SecTag><SecTag type="DISCUSS"><sec sec-type="discussion"><title><text><SENT sid="45" pm="."><plain>DISCUSSION </plain></SENT>
</text></title><p><text><SENT sid="46" pm="."><plain>This case shows that some patients do not fit into a specific disease. </plain></SENT>
<SENT sid="47" pm="."><plain>Initially, this patient was considered to merely have small duct PSC due to the low levels of AST and ALT associated with the absence of interface hepatitis and no response to immunosuppression. </plain></SENT>
<SENT sid="48" pm="."><plain>Various reports have stated that some patients, mainly children, may present with cholangiopathies with features similar to those of AIH[11]. </plain></SENT>
<SENT sid="49" pm="."><plain>The diagnosis of small duct PSC is still being discussed, but a liver biopsy is mandatory for the diagnosis; however, liver histological findings of PSC are non-specific[4]. </plain></SENT>
</text></p><p><text><SENT sid="50" pm="."><plain>The pattern of AST and ALT noticed 4 years later in our patient caused our group to revaluate the first diagnosis. </plain></SENT>
<SENT sid="51" pm="."><plain>Based on the autoantibodies found and the presence of interface hepatitis and reinforced by more recent studies[6,7], we assumed that this patient had an ‘overlap syndrome’ and was presenting with features of PSC and AIH. </plain></SENT>
</text></p><p><text><SENT sid="52" pm="."><plain>Maintenance of the same enzymatic pattern, unrelated to the modalities or intensity of immunosuppression, led us to search for mutations on the ABCB4 gene and results were compatible with the diagnosis of PFIC3. </plain></SENT>
<SENT sid="53" pm="."><plain>PFIC3 patients complain of recurrent pruritus and/or jaundice with chronic high levels of serum γ-GT, typically 10 times the UL[12]. </plain></SENT>
</text></p><p><text><SENT sid="54" pm="."><plain>The cholestatic pattern observed in our patient, which for a long time was ascribed to small duct PSC, is the result of PFIC3. </plain></SENT>
<SENT sid="55" pm="."><plain>Our patient had an allele with a previously described mutation[13] and a new genetic variant: c.3680T&gt;C (p.Ile1227Thr), which has not been previously reported, in the allele transmitted by his mother. </plain></SENT>
<SENT sid="56" pm="."><plain>This allele is reported in the ExAC database to have a global frequency of 0.00082%, with bioinformatics analysis indicating that is a deleterious mutation. </plain></SENT>
</text></p><p><text><SENT sid="57" pm="."><plain>Our patient, who for a long time was considered to have a PSC-AIH overlap syndrome, had a rare cholestatic disease (PFIC3) and AIH type 1. </plain></SENT>
<SENT sid="58" pm="."><plain>The interesting association of PFIC3 and AIH type 1 has not been described in the literature. </plain></SENT>
<SENT sid="59" pm="."><plain>Nonetheless, the association PFIC3-AIH may be fortuitous and PFIC3 is probably less rare than usually thought. </plain></SENT>
<SENT sid="60" pm="."><plain>We report this case with the aim of raising awareness of this rare pathology and highlighting the importance of genetic testing of the ABCB4 gene in patients with autoimmune liver disease (mainly small duct PSC) with incomplete response to immunosuppressive treatment. </plain></SENT>
</text></p></sec></SecTag></body><back><fn-group><fn id="fn1-537-1-3366-1-10-20161219" fn-type="COI-statement"><p><text><SENT sid="61" pm="."><plain>Conflicts of Interests: The Authors declare that there are no competing interests. </plain></SENT>
</text></p></fn></fn-group><SecTag type="REF"><ref-list><title>REFERENCES</title><ref id="b1-537-1-3366-1-10-20161219"><text><SENT sid="62" pm="."><plain>1HeneghanMAYeomanADVermaSSmithADLonghiMSAutoimmune hepatitisLancet20133821433144423768844 </plain></SENT>
</text></ref><ref id="b2-537-1-3366-1-10-20161219"><text><SENT sid="63" pm="."><plain>2MannsMPLohseAWVerganiDAutoimmune hepatitis – Update 2015J Hepatol201562Suppl 1S1S18625920078 </plain></SENT>
</text></ref><ref id="b3-537-1-3366-1-10-20161219"><text><SENT sid="64" pm="."><plain>3HirschfieldGMKarlsenTHLindorKDAdamsDHPrimary sclerosing cholangitisLancet20133821587159923810223 </plain></SENT>
</text></ref><ref id="b4-537-1-3366-1-10-20161219"><text><SENT sid="65" pm="."><plain>4BeuersUBobergKMChapmanRWChazouillèresOInvernizziPJonesDEEASL Clinical Practice Guidelines: management of cholestatic liver diseasesJ Hepatol20095123726719501929 </plain></SENT>
</text></ref><ref id="b5-537-1-3366-1-10-20161219"><text><SENT sid="66" pm="."><plain>5BjornssonEOlssonRBergquistALindgrenSBradenBChapmanRWThe natural history of small-duct primary sclerosing cholangitisGastroenterology200813497598018395078 </plain></SENT>
</text></ref><ref id="b6-537-1-3366-1-10-20161219"><text><SENT sid="67" pm="."><plain>6BobergKMChapmanRWHirschfieldGMLohseAWMannsMPSchrumpfEOverlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issueJ Hepatol20115437438521067838 </plain></SENT>
</text></ref><ref id="b7-537-1-3366-1-10-20161219"><text><SENT sid="68" pm="."><plain>7RojasCPBodicharlaRCampuzano-ZuluagaGHernandezLRodriguezMMAutoimmune hepatitis and primary sclerosing cholangitis in children and adolescentsFetal Pediatr Pathol20143320220924754367 </plain></SENT>
</text></ref><ref id="b8-537-1-3366-1-10-20161219"><text><SENT sid="69" pm="."><plain>8CzajaAJCarpenterHAAutoimmune hepatitis with incidental histologic features of bile duct injuryHepatology20013465966511584360 </plain></SENT>
</text></ref><ref id="b9-537-1-3366-1-10-20161219"><text><SENT sid="70" pm="."><plain>9GotthardtDRunzHKeitelVFischerCFlechtenmacherCWirtenbergerMA mutation in the canalicular phospholipid transporter gene, ABCB4, is associated with cholestasis, ductopenia, and cirrhosis in adultsHepatology2008481157116618781607 </plain></SENT>
</text></ref><ref id="b10-537-1-3366-1-10-20161219"><text><SENT sid="71" pm="."><plain>10Davit-SpraulAGonzalesEBaussanCJacqueminEProgressive familial intrahepatic cholestasisOrphanet J Rare Dis20094119133130 </plain></SENT>
</text></ref><ref id="b11-537-1-3366-1-10-20161219"><text><SENT sid="72" pm="."><plain>11GregorioGVPortmannBKaraniJHarrisonPDonaldsonPTVerganiDAutoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective studyHepatology20013354455311230733 </plain></SENT>
</text></ref><ref id="b12-537-1-3366-1-10-20161219"><text><SENT sid="73" pm="."><plain>12Davit-SpraulAGonzalesEBaussanCJacqueminEThe spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspectsSemin Liv Dis201030134146 </plain></SENT>
</text></ref><ref id="b13-537-1-3366-1-10-20161219"><text><SENT sid="74" pm="."><plain>13LiuCAronowBJJeggaAGWangNMiethkeAMouryaRNovel resequencing chip customized to diagnose mutations in patients with inherited syndromes of intrahepatic cholestasisGastroenterology200713211912617241866 </plain></SENT>
</text></ref></ref-list></SecTag></back><floats-group><SecTag type="FIG"><fig id="f1-537-1-3366-1-10-20161219" position="float"><label>Figure 1</label><caption><p><text><SENT sid="75" pm="."><plain>Family genogram </plain></SENT>
</text></p></caption><graphic xlink:href="537_Fig1"/></fig></SecTag><SecTag type="FIG"><fig id="f2-537-1-3366-1-10-20161219" position="float"><label>Figure 2</label><caption><p><text><SENT sid="76" pm="."><plain>Evolution of serum aminotransferases and cholestatic enzymes </plain></SENT>
</text></p></caption><graphic xlink:href="537_Fig2"/></fig></SecTag><SecTag type="FIG"><fig id="f3-537-1-3366-1-10-20161219" position="float"><label>Figure 3</label><caption><p><text><SENT sid="77" pm="."><plain>Liver histology showing interface and intra-lobular necro-inflammatory activity </plain></SENT>
</text></p></caption><graphic xlink:href="537_Fig3"/></fig></SecTag></floats-group></article>
